Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The information when a cancer has metastasized (spread). What proof do we have that CTC's need to be examined?
1. Eisai Inc. RNS dated 2nd Jan 2024.
https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html
2. Astrazeneca announcement dated 24th April 2024.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
3. Angle Plc announcement dated 4th Jan 2024 "Breakthrough clinical results".
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Waiting the takeover bid!
All IMHO.
I don't think it will be long before they get more contracts from both them AND other massive Plc's in the World. People should not forget that Angle Plc can do business with almost any Company anywhere in the entire WORLD. The World is a big place is it not! As I have said the RNS of 4th Jan "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" I think is going to make Angle Millions. In demonstrating circulating tumour cells (CTC's) when analysed give additional, valuable information over and above that routinely obtained via the standard CtDNA analysis HAS GOT TO GET MORE CONTRACTS. We now know standard CtDNA analysis offered by the likes of Illumina and Thermo Fisher do NOT obtain all the information available about the cancer's status. This makes "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" simply a MUST HAVE................ and Angle offer this service ALREADY. This is going to be TRANSFORMATIONAL for Angle IMHO. Any Company starting a cancer drug trial involving ANY CANCER that has metastasized WILL WANT THIS ADDITIONL INFORMATION. A COMPLETE *****NO BRAINER*****.
I suspect Angle will get overwhelmed with orders........... really.
All IMHO.
The significance of the announcement on 4th Jan simply *****will NOT be ignored***** by the industry.
Let's assume your Company wants to carry out a drug trial using your Companies new promising cancer drug.
The drug is for use sometimes after the cancer has spread (metastasized). That means circulating tumour cells (CTC's) are present in the blood. Angles's Parsortix machine can "catch" these cells intact and indeed 99% of the time are STILL ALIVE for analysis. Angle Plc's RNS of 4th Jan has found that when comparing the CtDna results (of DNA fragments in blood) to exactly the same analysis of ***circulating tumour cells (CTC's)*** there are remarkable unexpected differences giving further clues as to the status of the cancer during treatment. Do you:-
A) Want to obtain this information during your very expensive drug trial to find out this information.
B) Ignore this additional expense to get the additional information and pray it is not that important because if it is your Company will have lost the opportunity and indeed you might get sacked for being totally incompetent.
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
About to go positive I fear!
15p/16p now.
LOL!!!!
To me there are 3 things that are really important here. First and second we know they are talking to both Eisai In. (a top 100 Japanese Company AND now Astrazeneca (Top 100 UK Plc). Then to me the announcement of 4th January. Why? Because ANY Company doing a drug trial involving a metastasized cancer SIMPLY MUST AS THAT RNS says carry out "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample". See:-
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Failure to do an analysis on both the CtDNA and CTC's (Circulating tumour cells) after AGL's RNS explaining the additional important information they found is NOT AN OPTION. It would be a complete *****dereliction of duty!*****
When the first contract lands for this service the £1.60 spike on FDA approval might again be reached!!!!
All IMHO.
Barno61
"A solid broker rating of 70p which sounds sensible and achievable.".
==============================
I have hardly ever called a brokers "sp target" low.
IMHO 70p now is, ebnen with the sp @ 15.5p.
Illumina, or Thermo Fisher, or another Company *** IN THE ENTIRE WORLD *** is going to realise they need live, intact circulating tumour cells to test............................................ as have EISAI INC. (top 100 Japanese Co. and now AstraZeneca) then IMHO that is LOW. The Parsortix device delivers (99% of the time) "Live" intact circulating tumour cells to test.........................................SIMPLES!!!
And the sp is not even back to 18p. BEYOND ridiculous IMHO!!!!!!!!
All IMHO.
Reducing my holding what had started to get rather too large! However AGL in still my biggest investment..............
To me there are 3 things that are really important here. First and second we know they are talking to both Eisai In. (a top 100 Japanese Company AND now Astrazeneca. Then to me the announcement of 4th January. Why? Because ANY Company doing a drug trial involving a metastasized cancer SIMPLY MUST AS THAT RNS says carry out "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample". See:-
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Failure to do an analysis on both the CtDNA and CTC's (Circulating tumour cells) after AGL's RNS explaining the additional important information they found is NOT AN OPTION. It would be a complete dereliction of duty!
When the first contract lands for this service the £1.60 spike on FDA approval might again be reached!!!!
All IMHO.
See these, and where this is going I believe..............
https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
The following one is ALL IMPORTANT !!!! Join the dots............
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Up more - 32%.
18p plus on the cards.
All IMHO.
Buys flooding in now folks!!!!!!!!!!!!
Up 26.53%
Astrazeneca contract RNS!
Rececent announcements regarding HER2..........................
Join the dots...........
========================
Also very important about the RNS of 4th Jan "Angle PLC Breakthrough clinical results (5877Y)", see link below.:-
Companies doing Cancer drug trials will NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Yipeeee!!!!!!!!
Up 32.65%.
Astrazeneca contract!
AstraZeneca agreement !
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
Cjh6309
"And if it goes up another 30% tomorrow, then who’s the idiot! Cannot understand people who sell too quickly knowing the strong possibility of positive news just around the corner.".
=======================================================
If it goes up more tomorrow then I'm ok with that. I'll settle for the 70% I've banked.
Good luck all.
I bought @ 18.5p and sole @ 32p !
Carter19.
Eh?
Hello.